NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials
Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction-associated steatohepatitis (MASH; MASH with metabolic dysfunction-associated steatotic liver disease score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® te chnology designed to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for opti...
Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Tags: Research Article Source Type: research

NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction –associated steatohepatitis clinical trials
Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction–associated steatohepatitis (MASH; MASH with non-alcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® technology des igned to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for optimal selectio...
Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Source Type: research

Comprehensive gene profiling of the metabolic landscape of humanized livers in mice
The human liver transcriptome is complex and highly dynamic, e.g., one gene may produce multiple distinct transcripts, each with distinct posttranscriptional modifications. Direct knowledge of the transcriptome dynamics, however, is largely obscured by the inaccessibility of human liver to treatments and the insufficient annotation of the human liver transcriptome at transcript and RNA modifications levels. (Source: Journal of Hepatology)
Source: Journal of Hepatology - December 2, 2023 Category: Gastroenterology Authors: Chengfei Jiang, Ping Li, Yonghe Ma, Nao Yoneda, Kenji Kawai, Shotaro Uehara, Yasuyuki Ohnishi, Hiroshi Suemizu, Haiming Cao Tags: Research Article Source Type: research

MASLD emerging from the fog of fatty liver
The recent changes in the nomenclature of what has been defined for more than two decades as “non-alcoholic fatty liver disease” (NAFLD) derive from the lack of a clear pathophysiological framing and a longstanding uneasiness in using terms such as “alcoholic” and “fatty” for the hepatic manifestation of a systemic metabolic derangement mostly characterized by cardiovascular out comes. Along these lines, the term “non-alcoholic” did not accurately capture the aetiology of the disease. For instance, individuals with risk factors for NAFLD, such as type 2 diabetes (T2DM), who consume more alcohol than the rel...
Source: Journal of Hepatology - November 30, 2023 Category: Gastroenterology Authors: Giulio Marchesini, Roberto Vettor, Massimo Pinzani Tags: Editorial Source Type: research

Corrigendum to “Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation” [J Hepatol (2023) 645–656]
It has come to our attention that there was an error in Fig.  4G (left panel) of our manuscript. The size of the protein Flag-3ABC was incorrectly labelled as ‘75 kDa’ instead of its correct size ‘38 kDa’. This is corrected in the updated figure below. We apologise for any inconvenience caused. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 30, 2023 Category: Gastroenterology Authors: Ombretta Colasanti, Rani Burm, Hao-En Huang, Tobias Riedl, Jannik Traut, Nadine Gillich, Teng-Feng Li, Laura Corneillie, Suzanne Faure-Dupuy, Oliver Gr ünvogel, Danijela Heide, Ji-Young Lee, Cong Si Tran, Uta Merle, Maria Chironna, Florian F.W. Vondran, Tags: Corrigendum Source Type: research

Suboptimal hydration status increases the risk of incident MASLD: A pediatric cohort study
We have thoroughly reviewed the article written by Rinella et  al.,1 which presented the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD). Following screening for hepatic steatosis, the assessment of MASLD involved several key parameters, which are closely related to metabolic function including BMI, waist circumference, bloo d pressure, and blood biochemistry test indexes.1 These parameters are widely used in epidemiological studies pertaining to child and adolescent health. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Menglong Li, Huidi Xiao, Yeerlin Asihaer, Yingfeng Wu, Yifei Hu Tags: Letter to the Editor Source Type: research

Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms
The Banff Liver Working Group recently published consensus recommendations for steatosis assessment in donor liver biopsy, but few studies reported their use and no automated deep-learning algorithms based on the proposed criteria have been developed so far. We evaluated Banff recommendations on a large monocentric series of donor liver needle biopsies by comparing the pathologists score with that of a convolutional neural networks (CNN) we specifically developed for automated steatosis assessment. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Alessandro Gambella, Massimo Salvi, Luca Molinaro, Damiano Patrono, Paola Cassoni, Mauro Papotti, Renato Romagnoli, Filippo Molinari Tags: Research Article Source Type: research

Increase in HDV replication during steroid therapy – potential implications for testing and treatment strategies
We read with great interest the new clinical practice guidelines (CPGs) on hepatitis delta virus (HDV) infection as published in a recent issue of the Journal.1 The new guideline advocates widespread testing of HBsAg-positive individuals for co-infection with HDV, as previous studies have shown that risk-based testing leads to under-diagnosis and missed opportunities for linkage to care.2 The CPGs also support consideration of antiviral therapy in all individuals with chronic hepatitis D (CHD), given the high risk of progression to advanced chronic liver disease and liver cancer. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Lesley A. Patmore, Annemiek A. van der Eijk, Harry L.A. Janssen, Robert A. de Man, Milan J. Sonneveld Tags: Letter to the Editor Source Type: research

ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort
This study showed that ARID3A expression is significantly increased in hepatic macrophages and circulating monocytes in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), correlating with disease severity and specific biochemical markers 1. Previous genetic analyses in Chinese individuals demonstrated that the ARID3A variant rs2238574 modulates the expression of the ARID3A protein and promotes the development of PBC 2. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Beata Kruk, Roman Liebe, Susanne N. Weber, Piotr Milkiewicz, Marcin Krawczyk Tags: Letter to the Editor Source Type: research

Beyond Body Weight: Diversified Presentation of MASLD in Lean, Overweight, and Obese Participants
This study was funded by the National Natural Science Foundation of China grant nos. 81922016 (YFS), and 82200659 (XF); and the Natural Science Foundation of Shandong Province grant no. ZR2022QH002 (XF). (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Xiude Fan, Yingzhou Shi, Junming Han, Yongfeng Song, Jiajun Zhao Tags: Letter to the Editor Source Type: research

Suboptimal hydration status increases the risk of incident MAFLD: a pediatric cohort study
We have thoroughly reviewed the article written by Rinella et al. 1 which presented the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD), especially among pediatric population. Following screening for hepatic steatosis, the assessment of MASLD involved several key parameters, which are closely related to metabolic function including body mass index (BMI), waist circumference, blood pressure, and blood biochemistry test indexes 1. These parameters are widely used in epidemiological studies pertaining to child and adolescent health. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Menglong Li, Huidi Xiao, Yeerlin Asihaer, Yingfeng Wu, Yifei Hu Tags: Letter to the Editor Source Type: research

Preliminary Fatty Liver Disease Grading Using General-Purpose Online Large Language Models: ChatGPT-4 or Bard?
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent metabolic disorder,1 pathologically characterized by excessive fat accumulation in the liver. Timely pathological staging and targeted intervention are essential for preventing disease progression and improving outcomes. Liver biopsy is gold standard for staging NAFLD, but the interpretation requires specialized pathology expertise. In this context, artificial intelligence (AI) may hold promise in aiding NAFLD pathological diagnosis, especially for regions where pathology specialists are limited. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Yiwen Zhang, Hanyun Liu, Bin Sheng, Yih Chung Tham, Hongwei Ji Tags: Letter to the Editor Source Type: research

Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: considerations for new and existing therapies
We recently read the AASLD and EASL 2022 HBV/HDV treatment endpoints and study design conference consensus statement with great interest1. AASLD and EASL recommended “functional cure” as the primary endpoint for new HBV therapeutics under development, defined as HBsAg loss(S-loss) using a conventional HBsAg assay(limit of detection 0.05IU/mL) and HBV DNA below the lower limit of quantification( (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 28, 2023 Category: Gastroenterology Authors: Mark Anderson, Vera Holzmayer, Michael Stec, Gavin Cloherty, Seng Gee Lim Tags: Letter to the Editor Source Type: research

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 26, 2023 Category: Gastroenterology Authors: The Polaris Observatory Collaborators Tags: Research Article Source Type: research

The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories
This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. (Source: Journal of Hepatology)
Source: Journal of Hepatology - November 26, 2023 Category: Gastroenterology Authors: The Polaris Observatory Collaborators Tags: Research Article Source Type: research